Solid formulation
A solid dosage form for injection and a method of making said dosage form wherein the dosage form has a moisture content of 5% (w/w) or less. The solid dosage form comprises a dried matrix including a first excipient and 0.01 to 50% (w/w) or more than 50% and up to 80% (w/w) of a therapeutic peptide; and one or more additional excipients and at least 5% (w/w) of CMC, based on the total weight of the solid dosage form, wherein the dosage form has a width of 0.5 mm to 2 mm.
1. A solid dosage form for needle-free injection having a moisture content of between 1 and 5% (w/w), the solid dosage form comprising:
a dried matrix including at least a first excipient and 0.01 to 50% (w/w) of a therapeutic protein; and
one or more additional excipients and 5 to 95% (w/w), based on the total weight of the solid dosage form, of carboxymethylcellulose (CMC) blended in the dosage form, wherein the dosage form has a width of 0.5 mm to 2 mm, wherein the compressive strength of the dosage form is at least 80 MPa and is 168 MPa or less.
2. A solid dosage form according to claim 1 , wherein the moisture content is between 2% and 3% (w/w).
3. A solid dosage form according to claim 1 , wherein the first excipient and/or at least one or more additional excipients is a bulking agent.
4. A solid dosage form according to claim 3 , wherein the bulking agent is a polyol.
5. A solid dosage form according to claim 4 , wherein the bulking agent is mannitol.
6. A solid dosage form according to claim 1 , wherein the protein is a peptide.
7. A solid dosage form according to claim 1 , wherein the width of the dosage form is from 0.50 to 1 mm.
8. A solid dosage form according to claim 1 , wherein the length of the dosage form is from 2 to 6 mm.
9. A solid dosage form according to claim 1 , wherein the total weight of the solid dosage form is from 1 to 5 mg.
10. A solid dosage form according to claim 6 , wherein the peptide is octreotide and for use in the treatment or prevention of intestinal tumours or metastatic carcinoid tumours or acromegaly.
11. A solid dosage form according to claim 6 , wherein the peptide is PTH or a fragment thereof for use in the treatment of solitary bone cysts or hypoparathyroidism.
12. A solid dosage form according to claim 6 , wherein the peptide is exenatide or liraglutide for use in the treatment or prevention of diabetes mellitus type 2.
13. A drug delivery device or packaged drug for use with a drug delivery device which comprises a solid dosage form according to claim 1 .
14. A method of treating intestinal tumours, metastatic carcinoid tumours, acromegaly, solitary bone cysts, hypoparathyroidism or diabetes mellitus type 2, said method comprising administering to a subject in need a therapeutically effective amount of a solid dosage form as defined in claim 1 .
15. A solid dosage form according to claim 6 , wherein the peptide is octreotide, PTH 1-34, exenatide or liraglutide.
16. A solid dosage form according to claim 8 , wherein the width of the dosage is 0.85 mm.
17. A solid dosage form according to claim 9 , wherein the length of the dosage form is 4 mm.
18. A solid dosage form according to claim 10 , wherein the compressive strength of the dosage form is at least 100 MPa.